The influence of storage vessel, incubation time and temperature on the stability of 99mTc-tetrofosmin
Keywords:
99mTc-tetrofosmin, Radio Chemical Purity (RCP), Temperature, PhosphinesAbstract
Aim: To determine the stability and radio chemical purity (RCP) of 99mTc-tetrofosmin kept for different time intervalsof up to 12 hours, the maximum recommended by the manufacturers, at different temperatures (18-25º C or room temperature,32ºC & 2-8ºC), in both reactive equipment vials or in syringes, and to determine whether shorter or longerincubation times, other than the recommended 20 minute period, could affect the RCP of doses of the radiopharmaceutical.Materials and Methods: 40 vials of phosphine were labelled in accordance with manufacturer’s recommendations.Three different storage temperature conditions were studied, in order to determine how possible extremes may affectdosages of the drug. Results: The average RCP percentages of the radiofarmaceutical incubated in vials and syringeswere 95.79±2.32 & 96.16±2.32 respectively, with no signifi cant differences observed. Stability at different temperaturesand different time intervals was over 90% in all cases. Conclusions: The 99mTc-tetrofosmin complex remains stable for12 hours, whether it is incubated in the original reactive equipment or within insulin syringes with needle. Additionally,the radiopharmaceutical also remained stable at the different studied storage temperatures and at all time intervalsfor up to 12 hours.Downloads
References
Blasco R, Rodríguez Zarauz J, Marcos MP, Gely P, Villares L, La Banda P. Complejo de fosfinas. Rev Esp Med Nucl. 1995; 14 (2): 59-65.
Nelly JD, Forster AM, Higley B, Archer CM, Broker FS, Canning LR, Chiu KW, Edwards B, Gil HK, McPartlin M, Nagle KR, Latham IA, Pickett RD, Storey AE, Webbon PM. Technetium-99m-tetrofosmin as a new radiopharmaceutical for myocardial perfusion imaging. J Nucl Med. 1993; 34: 222-227.
Forster AM, Storey AE, Archer CM, Tagle KR, Broker FS, Edwards B, Gill HK, Nelly JD, McPartlin M. Structural characterization of the new myocardial imaging agent technetium-99m tetrofosmin (99mTc-P53). J Nucl Med. 1992; 33: 850.
Package Insert, Mayo 2003. MYOVIEW®. Equipo reactivo para la preparación inyectable de Tetrofosmina y de Tecnecio (99mTc). Amersham Health. Ronda de Poniente, 12 – Euronova. 28760 Tres Cantos. Madrid. España.
Ramirez de Arellano I, Piera C, Pavia J, Setoain J. Experiences in setting up the first centralizad radiopharmacy in Spain. Nucl Med Commun. 1999; 20 (3): 270-85.
Cagnolini A, Whitener D, Jurisson S. Comparison of the kit performance of three 99mTc-myocardial perfusion agents. Nucl Med Biol. 1998; 25: 435-439.
Downloads
Published
How to Cite
Issue
Section
License
The articles, which are published in this journal, are subject to the following terms in relation to the rights of patrimonial or exploitation:
- The authors will keep their copyright and guarantee to the journal the right of first publication of their work, which will be distributed with a Creative Commons BY-NC-SA 4.0 license that allows third parties to reuse the work whenever its author, quote the original source and do not make commercial use of it.
b. The authors may adopt other non-exclusive licensing agreements for the distribution of the published version of the work (e.g., deposit it in an institutional telematic file or publish it in a monographic volume) provided that the original source of its publication is indicated.
c. Authors are allowed and advised to disseminate their work through the Internet (e.g. in institutional repositories or on their website) before and during the submission process, which can produce interesting exchanges and increase citations of the published work. (See The effect of open access).
